Trial reportInternational journal of clinical oncology2026
Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.
Trial report in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe combination of encorafenib plus binimetinib (ENC + BIN) is approved for the treatment of BRAF V600-mutated thyroid cancer in Japan, based on a phase 2 trial. We update the efficacy and safety data for ENC + BIN of this phase 2 trial after prolonged follow-up.
methodsThis multicenter, open-label, uncontrolled phase 2 trial evaluated the efficacy and safety of ENC + BIN in patients with unresectable locally advanced or metastatic BRAF V600-mutated thyroid cancer that was not amenable to curative treatment, who were refractory/intolerant to ≥ 1 previous vascular endothelial growth factor receptor-targeted regimens, or were considered ineligible for these. The primary endpoint was the objective response rate (ORR). The secondary endpoints included progression-free survival (PFS) and overall survival (OS).
resultsWe enrolled 22 patients: 17 with differentiated thyroid carcinoma (DTC) and 5 with anaplastic thyroid carcinoma (ATC). During a prolonged period with a median follow-up of 28.7 months (range: 3.4-40.6), 3 additional patients with DTC achieved partial responses, increasing the ORR to 68.2% (15/22 patients with either DTC or ATC). Medians for PFS and OS were not reached for DTC and 17.7 and 24.3 months, respectively, for ATC. Common adverse events were eye disorder (5/12), infections and infestations (4/12), and skin and subcutaneous tissue disorder (4/12) after > 360 days; no new safety signals were identified during the extended follow-up period.
conclusionsWith a > 24-month median follow-up, this analysis indicates that ENC + BIN provides sustained tumor responses in patients with BRAF V600-mutated thyroid cancer. The long-term safety profile is consistent with previous reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.